Literature DB >> 18295556

High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study.

Gholamreza Bahrami1, Bahareh Mohammadi, Sajjad Sisakhtnezhad.   

Abstract

A sensitive and rapid method is described for determination of clopidogrel carboxylic acid (CCA), the inactive metabolite of anti platelet agent, clopidogrel, in human serum. The analytical procedure involves liquid-liquid extraction of the analyte and an internal standard (phenytoin) with ethyl acetate. A mobile phase consisting of 0.05 M phosphate buffer containing triethylamine (0.5 mL/L; pH 5.7) and acetonitrile (56:44 v/v) was used and chromatographic separation was achieved using C18 analytical column at detector wavelength of 220 nm. The calibration curves were linear over a concentration range of 0.05-10 microg/mL of CCA in human serum. The total run time of analysis was 5.5 min and the lower limits of detection (LOD) and quantification (LOQ) were 0.02 and 0.05 microg/mL, respectively. The method validation was carried out in terms of specificity, sensitivity, linearity, precision, accuracy and stability. The validated method was applied in a randomized cross-over bioequivalence study of two different clopidogrel preparations in 24 healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295556     DOI: 10.1016/j.jchromb.2008.01.049

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.

Authors:  Cody J Peer; Shawn D Spencer; Dustin A H VanDenBerg; Michael A Pacanowski; Richard B Horenstein; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-11-26       Impact factor: 3.205

2.  A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation.

Authors:  Yae Min Park; Taehoon Ahn; Kyounghoon Lee; Kwen-Chul Shin; Eul Sik Jung; Dong Su Shin; Myeong Gun Kim; Woong Chol Kang; Seung Hwan Han; In Suck Choi; Eak Kyun Shin
Journal:  Korean Circ J       Date:  2012-07-26       Impact factor: 3.243

3.  Validation of a method for quantitation of the clopidogrel active metabolite, clopidogrel, clopidogrel carboxylic acid, and 2-oxo-clopidogrel in feline plasma.

Authors:  Janne G Lyngby; Michael H Court; Pamela M Lee
Journal:  J Vet Cardiol       Date:  2017-06-09       Impact factor: 1.701

4.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.

Authors:  Helena Leonie Hanae Loer; Denise Türk; José David Gómez-Mantilla; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

5.  The effects of clopidogrel and omeprazole on platelet function in normal dogs.

Authors:  B E Thames; J Lovvorn; M G Papich; R Wills; T Archer; A Mackin; J Thomason
Journal:  J Vet Pharmacol Ther       Date:  2016-07-24       Impact factor: 1.786

6.  Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study.

Authors:  Octavian Croitoru; Adela-Maria Spiridon; Ionela Belu; Adina Turcu-Ştiolică; Johny Neamţu
Journal:  J Anal Methods Chem       Date:  2015-12-29       Impact factor: 2.193

7.  Comparison of Multiplate, Platelet Function Analyzer-200, and Plateletworks in Healthy Dogs Treated with Aspirin and Clopidogrel.

Authors:  S Saati; A C G Abrams-Ogg; S L Blois; R D Wood
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.